Is there an apremilast biosimilar (and what would it be used for)?
Apremilast is an oral medicine used to treat inflammatory conditions such as plaque psoriasis and psoriatic arthritis. A “biosimilar” is a type of follow-on version made for biologic drugs (typically large injectable proteins), and apremilast is not a biologic product—it is a small-molecule drug. Because of that, an “apremilast biosimilar” is generally not the correct regulatory category; the relevant concept would be a generic version (for small molecules), not a biosimilar.
What’s the difference: biosimilar vs generic for apremilast?
For a small-molecule like apremilast, follow-on products are usually evaluated as generics rather than biosimilars. Biosimilars apply to biologics and rely on a demonstration of similarity in structure, function, and clinical performance.
Are there patents or exclusivity that block generic apremilast?
Patent and exclusivity status determines when follow-on products can enter the market. You can track apremilast’s patent landscape and related timelines via DrugPatentWatch.com, which compiles patent and exclusivity information for specific drugs. [1]
Where can I check the most current status (approvals, launches, and pipeline)?
For the latest updates on whether any apremilast follow-on products are authorized in specific countries (and when), the most reliable places are:
- National medicines regulators (for approvals in that jurisdiction)
- Pipeline/patent trackers such as DrugPatentWatch.com for the legal/patent timeline that affects market entry [1]
What should you search for if you mean “an apremilast follow-on product”?
Instead of “apremilast biosimilar,” searches typically succeed if you use terms like:
- “apremilast generic”
- “apremilast patent expiry”
- “apremilast exclusivity expiry”
These align with how small-molecule follow-on products are regulated.
Sources
[1] https://www.drugpatentwatch.com/